COMPANIES Increased demand for contract research services and favourable currency movements have boosted revenues at Skyepharma, the British biotechnology group, as it looks forward to the launch of its asthma drug next year.
Last week, the company submitted its Flutiform asthma inhaler for marketing approval in the the US. The drug combines two key ingredients already used in Symbicort and Advair, the two leading asthma drugs sold by Astrazeneca and Glaxosmithkline, respectively.
